Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
Symbol TNFSF10 contributors: mct - updated : 25-10-2017
HGNC name tumor necrosis factor (ligand) superfamily, member 10
HGNC id 11925
Location 3q26.31      Physical location : 172.223.298 - 172.241.297
Synonym name
  • Apo-2 ligand
  • TNF-related apoptosis inducing ligand TRAIL
  • tumor necrosis factor apoptosis-inducing ligand splice variant delta
  • CD253 antigen
  • protein TRAIL
  • Synonym symbol(s) APO2L, TRAIL, TL2, CD253
    TYPE functioning gene
    STRUCTURE 18.00 kb     5 Exon(s)
    10 Kb 5' upstream gene genomic sequence study
    regulatory sequence Promoter
    Binding site   transcription factor
    text structure
  • promoter contains several potential responsive elements, which are associated with different transcription factors
  • MAPPING cloned Y linked N status confirmed
    Physical map
    GPR160 3q26.2-q27 G protein-coupled receptor 160 LOC389176 3 similar to Histone-lysine N-methyltransferase, H4 lysine-20 specific (Histone H4-K20 methyltransferase) (H4-K20-HMTase) (SET domain-containing protein 8) (PR/SET domain-containing protein 07) (PR/SET07) (PR-Set7) PHC3 3q26.32 polyhomeotic like 3 (Drosophila) PRKCI 3q26.3 protein kinase C, iota SKIL 3q26 SKI-like CLDN11 3q26.2-q26.3 claudin 11 (oligodendrocyte transmembrane protein) FLJ37228 3q26.31 hypothetical protein FLJ37228 KIAA1613 3q26.31 KIAA1613 protein LOC391591 3 similar to ribosomal protein L28; 60S ribosomal protein L28 LOC200916 3q26.31 similar to RIKEN cDNA 3110001N18 EIF5A2 3q25-q27 eukaryotic translation initiation factor 5A2 SLC2A2 3q26.2-q26.3 solute carrier family 2 (facilitated glucose transporter), member 2 KIAA0551 3q26.31 Traf2 and NCK interacting kinase PLD1 3q26 phospholipase D1, phophatidylcholine-specific LOC389177 3 LOC389177 FAD104 3q26.31 FAD104 LOC391592 3 similar to basic leucine zipper and W2 domains 1 GHSR 3q26.2 growth hormone secretagogue receptor TNFSF10 3q26 tumor necrosis factor (ligand) superfamily, member 10 LOC339858 3q26.31 similar to High-affinity copper uptake protein 1 (hCTR1) (Copper transporter 1) KIAA1363 3q26.31-q26.32 KIAA1363 protein ECT2 3q26.1-q26.2 epithelial cell transforming sequence 2 oncogene RNU4P4 3q26.32 RNA, U4 small nuclear pseudogene 4 NYD-SP12 3q26.32 NYD-SP12 protein NLGN1 3q26.32 neuroligin 1 LOC344666 3q26.32 similar to 60S ribosomal protein L8 LOC254827 3q26.32-q26.33 hypothetical protein LOC254827
    TRANSCRIPTS type messenger
    identificationnb exonstypebpproduct
    ProteinkDaAAspecific expressionYearPubmed
    3 - 1805 - 101 - 2000 11095979
    5 - 1953 - 281 - 2000 11095979
    2 - 1334 - 65 - 2000 11095979
    Type widely
    constitutive of
       expressed in (based on citations)
    SystemOrgan level 1Organ level 2Organ level 3Organ level 4LevelPubmedSpeciesStageRna symbol
    Lymphoid/Immunespleen   predominantly
    Reproductivemale systemprostate   
    SystemTissueTissue level 1Tissue level 2LevelPubmedSpeciesStageRna symbol
    cell lineage
    cell lines
    at STAGE
  • an extracellular C terminus
  • conjugated GlycoP
    mono polymer homomer , trimer
    interspecies homolog to murine Tnfsf10
  • tumor necrosis factor (ligand) superfamily
  • CATEGORY signaling cytokine
    SUBCELLULAR LOCALIZATION     plasma membrane
    text type II transmembrane glycoprotein
    basic FUNCTION
  • TNF-related apoptosis inducing ligand (TRAIL), independent of DAP3
  • inducing appoptosis in the brain
  • with TNFRSF10A and TNFRSF10B, play an important role in inflammation
  • induces apoptosis through its cognate receptors death receptor TNFRSF10A and TNFRSF10B, preferentially in malignant cells
  • promising for anticancer therapy because it induces apoptosis in cancer cells with little or no toxicity to normal cells
  • TNFSF10 and CASP8 expression levels were positively correlated with apoptosis in osteosarcoma
  • CELLULAR PROCESS cell life, cell death/apoptosis
    text preferentially inducing apoptosis in transformed and tumor cells
    signaling signal transduction
    JNK pathway
    a component
    small molecule
  • TNFRSF10,triggering the activation of MAPK8/JNK, caspase 8, caspase 3
  • APO2L ligand
  • CFLAR (is not only a central antiapoptotic modulator of TNFSF10-mediated apoptosis but also an inhibitor of TNFSF10-induced NF-kappaB activation and subsequent proinflammatory target gene expression)
  • interacting with PLSCR3 (TNFSF10-induced activation of PKC-delta mediates regulation of the PLSCR3-induced changes in cardiolipin)
  • interacting with HOMER1
  • TRADD plays a survival role in TNFSF10 signaling
  • interacting with TRADD (TRADD is critical for resistance to TNFSF10-induced cell death through NFKB activation)
  • TNFSF10-mediated tumoricidal activity of macrophages can be stimulated by SERPINF1
  • SERPINF1 mediates the induction of TNFSF10 expression by PPARG
  • PPP3R1-induced TNFSF10 expression is mediated by NFKB
  • interaction of SH3KBP1 with MAP3K4 was increased during the late phase of TNFSF10 incubation, suggesting that sustained MAPK14 and HSPB1 phosphorylation protects cells by preventing further cell death
  • TNK2 is required for TNFSF10-induced cell death in multiple epithelial cell lines
  • TNFSF10 -induced lysosomal membrane permeabilization is mediated by the multifunctional sorting protein PACS2 and repressed by the E3 ligases BIRC2 and BIRC3
  • CTSD enzymatic activity is a new factor affecting sensitivity of breast cancer cells to TNFSF10
  • FGF2 was superior, stimulating cell infiltration and angiogenesis better than TNFSF10 and VEGFA
  • cell & other
    activated by in response to IFNA, IFNB
    PPARG, that is an activator of TNFSF10 expression in macrophages
    repressed by EGR1
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral     --over  
    in low grade astrocytomas, glioblastomas
    Variant & Polymorphism
    Candidate gene
    Therapy target
    potential implications for cancer therapy using TNFSF10-receptor agonists
    combination of WEE1 inhibitor and TNFSF10 could provide a novel combination for the treatment of basal/triple-negative breast cancer